Respiri - First primary care setting client win
Respiri has announced another client win, this time in a primary care setting for remote patient monitoring (RPM) services using its wheezo device. The latest commercial deal (the fifth for the Respiri Access Telehealth collaboration) is with the Medical Center of Conyers, a family practice based in Georgia, in the US, and will involve managing patients suffering from asthma and chronic obstructive pulmonary disease (COPD). The first patients have already been brought onboard, which takes Respiri closer to realising first reimbursement claims in early 2023, under the Centers for Medicare and Medicaid Services’ (CMS’s) current procedural terminology codes for RPM. This also marks the fifth US state to have wheezo available in the RPM setting and the third win in the last 20 days, indicating improving commercial traction.Respiri is engaged in the research, development and commercialization of medical devices, and the development of mobile health applications. Co.'s reportable segments are Australia and Israel.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.